Aging is known to be associated with an increased prevalence of diabetes. In 2005, the CDC reported an estimated prevalence of diabetes in the U.S. to be 2% in the 20-39 age group, 10% in the 40-59 age group, and 21% in the 60 or older age group. Glucagon-like peptide-1 (GLP-1), a hormone secreted postprandially from enteroendocrine L cells, has potent insulinotropic effects. In addition, it suppresses glucagon secretion during hyperglycemia, delays gastric emptying, slows gut motility, and increases satiety; all work in synergy to normalize hyperglycemia in diabetes. In this review, the authors summarize the biology of GLP-1, explore the latest development of GLP-1 analogs and GLP-1 receptor agonists for treatment of type 2 diabetes, and discuss how this new class of agents may be suitable for treating older patients with diabetes.
|Original language||English (US)|
|Number of pages||8|
|State||Published - Apr 1 2007|
ASJC Scopus subject areas
- Geriatrics and Gerontology